O
RNA

OrbiMed’s PROSENSA HLDGS N V ORD SHS (NLD) RNA Stock Holding History

OrbiMed’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-264,000
Closed -$3.33M – 152
2014
Q2 		$3.33M Buy
+264,000
New +$2.14M 0.04% 120

Other funds holding RNA

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VLKIM
Van Lanschot Kempen Investment Management Amsterdam, Netherlands $11.4B AUM 16.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Proxima Capital Management New York $21M AUM 3.49% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

OrbiMed's RNA Position: Q3 2014 in Review

OrbiMed sold out of PROSENSA HLDGS N V ORD SHS (NLD) (RNA) in Q3 2014, closing a stake of 264,000 shares — an estimated $3.33M sold.

OrbiMed first reported a position in RNA in Q2 2014 and held it in 1 quarter. The position peaked at $3.33M in Q2 2014. 32 funds tracked by Wall St. Rank hold RNA as of Q3 2014.

  • OrbiMed reported no remaining PROSENSA HLDGS N V ORD SHS (NLD) position as of Q3 2014 after selling out during the quarter.
  • OrbiMed sold 264,000 PROSENSA HLDGS N V ORD SHS (NLD) shares in Q3 2014, an estimated $3.33M.
  • OrbiMed first reported a position in PROSENSA HLDGS N V ORD SHS (NLD) in Q2 2014 and held it in 1 quarter.
  • OrbiMed's PROSENSA HLDGS N V ORD SHS (NLD) position peaked at $3.33M in Q2 2014.
  • 32 funds tracked by Wall St. Rank held PROSENSA HLDGS N V ORD SHS (NLD) as of Q3 2014.

Based on OrbiMed's 13F filing for Q3 2014, filed 14 Nov 2014.